NASDAQ$IOVA
Iovance Biotherapeutics Inc. · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Iovance Biotherapeutics Inc. reported Q2 2025 results showing increased product revenue from the Amtagvi launch.
The company generated $59.95 million in product revenue for the quarter, driven primarily by Amtagvi sales of $54.07 million. Net loss was $111.66 million or $0.33 per share, with operating loss of $113.77 million. Cash and cash equivalents stood at $132.47 million alongside short-term investments of $168.71 million.
- Product revenue reached $59.95 million, up significantly year-over-year due to Amtagvi commercialization.
- Amtagvi contributed $54.07 million while Proleukin added $5.88 million in the quarter.
- Net loss per share improved to $0.33 from $0.34 in the prior year period.
- Total assets were $907.44 million with strong liquidity position including $301.18 million in cash and short-term investments.
Headline financials
Revenue & EPS history
Iovance · Revenue · Quarterly
$60M
Revenue by segment
Iovance · $60M total across 2 segments · Q2 2025
- Amtagvi sales$54.1M—90.2%
- Proleukin sales$5.88M—9.8%
Forward guidance
No specific quantitative forward guidance disclosed in the filing.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-1.0%
Avg return
Earnings day
+2.1%
Avg return
5 days after
-1.2%
Avg return
30 days after
37%
20 / 54 earnings
Positive
+36.3%
Q4 2019
Best reaction
-45.1%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -13.2% | -12.7% | +3.4% | |
| Q4 2025 | +30.1% | +33.6% | +27.7% | |
| Q3 2025 | +27.9% | +46.4% | +21.5% | |
| Q1 2025 | -45.1% | -46.1% | -35.3% | |
| Q4 2024 | -19.4% | -23.0% | -32.3% | |
| Q3 2024 | -12.8% | -20.2% | -25.6% | |
| Q2 2024 | +35.3% | +46.5% | +36.6% | |
| Q1 2024 | -18.1% | -19.9% | -41.9% | |
| Q4 2023 | -8.9% | +72.3% | +67.9% | |
| Q3 2023 | -3.5% | -8.1% | +55.8% | |
| Q2 2023 | +7.8% | +0.1% | -17.7% | |
| Q1 2023 | +7.9% | +5.5% | +13.0% | |
| Q4 2022 | +1.8% | +2.5% | -14.2% | |
| Q3 2022 | +0.0% | -7.0% | -23.1% | |
| Q2 2022 | +1.2% | -0.2% | -8.8% | |
| Q1 2022 | -12.4% | -17.2% | -52.4% | |
| Q4 2021 | +10.2% | +9.4% | +20.5% | |
| Q3 2021 | +0.6% | -0.2% | -33.4% | |
| Q2 2021 | +3.2% | +2.1% | +10.1% | |
| Q1 2021 | -2.4% | -9.3% | -38.7% | |
| Q4 2020 | -5.4% | -5.3% | -27.3% | |
| Q3 2020 | +2.2% | -3.7% | +8.9% | |
| Q2 2020 | -5.3% | -8.8% | -0.7% | |
| Q1 2020 | +1.2% | +12.0% | -4.3% | |
| Q4 2019 | +36.3% | +33.3% | +29.4% | |
| Q3 2019 | -0.7% | +7.5% | +12.5% | |
| Q2 2019 | -3.5% | -8.6% | -14.6% | |
| Q1 2019 | -5.5% | -3.2% | +61.2% | |
| Q4 2018 | -1.7% | +7.8% | -9.0% | |
| Q3 2018 | -3.2% | -5.1% | +5.3% | |
| Q2 2018 | +6.9% | +6.5% | +23.3% | |
| Q1 2018 | +0.7% | +1.0% | -16.2% | |
| Q4 2017 | -8.6% | -11.8% | -21.2% | |
| Q3 2017 | -6.5% | +2.0% | +18.3% | |
| Q2 2017 | -5.1% | -4.3% | -1.7% | |
| Q1 2017 | -9.8% | -11.7% | -24.8% | |
| Q4 2016 | -1.3% | +2.7% | -10.1% | |
| Q3 2016 | +5.1% | +19.7% | +2.6% | |
| Q2 2016 | -2.1% | -1.5% | -11.1% | |
| Q1 2016 | +4.4% | — | — | |
| Q4 2015 | -5.4% | — | — | |
| Q3 2015 | — | — | — | |
| Q4 2014 | +18.7% | — | — | |
| Q1 2013 | -2.8% | — | — | |
| Q2 2013 | -2.8% | — | — | |
| Q4 2012 | +0.0% | — | — | |
| Q3 2012 | -20.0% | — | — | |
| Q2 2012 | -26.0% | — | — | |
| Q1 2012 | +2.6% | — | — | |
| Q4 2011 | -0.9% | — | — | |
| Q3 2011 | -0.8% | — | — | |
| Q2 2011 | -7.1% | — | — | |
| Q1 2011 | +6.1% | — | — | |
| Q4 2010 | +0.0% | — | — | |
| Q3 2010 | -4.5% | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro